177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate
Stanak M, Groessman N, Strohmaier C
Record ID 32018000352
Authors' objectives: The majority of prostate cancer patients have an overexpressed prostate specific membrane antigen (PSMA) that is a target for radionuclide therapy. Our aim was to review the current evidence on clinical effectiveness and safety of 177 Lutetium (Lu) labelled PSMA for metastatic castration-resistant prostate cancer (mCRPC) patients.
Authors' results and conclusions: No controlled trials were found to answer the research questions on clinical effectiveness. Concerning safety, we identified five prospective before-after studies with the total of 141 patients. The serious adverse event of study related death or the adverse event of discontinuation rate did not occur in either study. Grade 3-4 toxicities that occured were nephrotoxicity, hematotoxicity, hepatotoxicity, and bone pain flare. The risk of bias ranged from low to high and the GRADE assessed quality of evidence was low to very low.
Authors' recomendations: At present, we do not recommend 177Lu-PSMA for mCRPC patients for inclusion in the Austrian catalogue of benefits and we suggest a reevaluation in 2021.
Project Status: Completed
Year Published: 2019
URL for published report: http://eprints.aihta.at/1207/1/DSD_118.pdf
URL for additional information: http://eprints.aihta.at/1207/
English language abstract: An English language summary is available
Publication Type: Full HTA
- Prostatic Neoplasms, Castration-Resistant
- Prostate-Specific Antigen
- prostate cancer
- prostate specific membrane antigen
- castration resistant
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.